Display options
Cite
Patil SA, Addo JK, Deokar H, et al. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug Des. 2017;6(1)doi: 10.4172/2169-0138.1000143.
Patil, S. A., Addo, J. K., Deokar, H., Sun, S., Wang, J., Li, W., Suttle, D. P., Wang, W., Zhang, R., & Buolamwini, J. K. (2017). Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug designing : open access, 6(1), . https://doi.org/10.4172/2169-0138.1000143
Patil, Shivaputra A, et al. "Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-." Drug designing : open access vol. 6,1 (2017). doi: https://doi.org/10.4172/2169-0138.1000143
Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug Des. 2017 Mar;6(1). doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 01. PMID: 29354330; PMCID: PMC5771418.
Copy Download .nbib Format: NLM
Share it on

Drug Des. 2017 Mar;6(1). doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 01.

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-.

Drug designing : open access

Shivaputra A Patil, James K Addo, Hemantkumar Deokar, Shan Sun, Jin Wang, Wei Li, D Parker Suttle, Wei Wang, Ruiwen Zhang, John K Buolamwini

Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 847 Monroe Avenue, Suite 327, Memphis, TN 38163, USA.
  2. Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, 60064, USA.
  3. Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA.
  4. Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
  5. Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.

PMID: 29354330 PMCID: PMC5771418 DOI: 10.4172/2169-0138.1000143

Abstract

OBJECTIVE: There is an urgent need drugs against particularly difficult to treat solid tumors such as pancreatic, triple negative breast, lung, colon, metastatic prostate cancers and melanoma. Thus, the objective of this study was to synthesize compounds based computational modeling that indicated the pyrido[3,4-

METHODS: Compounds were synthesized by established methods and tested for antiproliferative activity against a broad range of human cancer cell lines, comprising HCT116 colon, HPAC, MIA PaCa-2 and Panc-1 pancreatic, MCF-7 and MDA-MB-468 breast, A375 and WM164 melanoma, A549 lung, and LNCaP, DU145 and PC3 prostate cancer lines. Computational docking was also undertaken.

RESULTS: The novel pyrido[3,4-

CONCLUSION: We have identified a novel series of pyrido[3,4-

Keywords: Anticancer agents; Breast cancer; Cell lines; Colon cancer; Lung cancer; Melanoma; Molecular docking; Pancreatic cancer; Prostate cancer; Pyrido[3,4-b]indole derivatives; Structure-activity relationships; Synthesis; β-carbolines

Conflict of interest statement

Conflicts US patents 8,329,723 and 8,927,570 have been issued based on this work.

References

  1. Curr Med Chem. 2008;15(17 ):1720-30 - PubMed
  2. Bioorg Med Chem. 2006 Oct 15;14(20):6998-7010 - PubMed
  3. Gastroenterology. 2014 Oct;147(4):893-902.e2 - PubMed
  4. Bioorg Med Chem. 2004 Sep 1;12(17):4613-23 - PubMed
  5. Nat Rev Drug Discov. 2014 Mar;13(3):179-96 - PubMed
  6. J Med Chem. 2015 Feb 12;58(3):1038-52 - PubMed
  7. Nat Med. 2004 Dec;10 (12 ):1321-8 - PubMed
  8. Eur J Med Chem. 2009 Feb;44(2):533-40 - PubMed
  9. Nat Commun. 2014 Oct 01;5:5086 - PubMed
  10. J Transl Med. 2012 Jul 09;10:85 - PubMed
  11. Science. 2006 May 26;312(5777):1175-8 - PubMed
  12. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5841-4 - PubMed
  13. Science. 1996 Nov 8;274(5289):948-53 - PubMed
  14. Mol Cancer Ther. 2015 Dec;14 (12 ):2850-63 - PubMed
  15. Eur J Med Chem. 2009 Oct;44(10):4153-61 - PubMed
  16. Angew Chem Int Ed Engl. 2011 Sep 5;50(37):8538-64 - PubMed
  17. Curr Cancer Drug Targets. 2005 Feb;5(1):57-68 - PubMed
  18. Nat Genet. 2009 May;41(5):544-52 - PubMed
  19. Bioorg Med Chem. 2008 Nov 15;16(22):9660-7 - PubMed
  20. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  21. J Med Chem. 2013 Jul 25;56(14 ):5979-83 - PubMed
  22. Chin Med. 2011 Mar 23;6(1):11 - PubMed
  23. Cancer Res. 1992 Aug 15;52(16):4478-83 - PubMed
  24. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3319-24 - PubMed
  25. Expert Opin Investig Drugs. 2008 Dec;17 (12 ):1865-82 - PubMed
  26. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  27. Science. 2004 Feb 6;303(5659):844-8 - PubMed
  28. Drugs. 2003;63(5):513-22; discussion 523-4 - PubMed
  29. ACS Med Chem Lett. 2013 Apr 02;4(5):466-9 - PubMed
  30. Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a001222 - PubMed
  31. Nature. 2014 Apr 3;508(7494):118-22 - PubMed
  32. J Cell Biochem. 1997 Mar 1;64(3):343-52 - PubMed
  33. Cancer Res. 2011 Apr 1;71(7):2750-60 - PubMed
  34. Curr Cancer Drug Targets. 2005 Feb;5(1):27-41 - PubMed
  35. Biochem Biophys Res Commun. 2004 Apr 23;317(1):128-32 - PubMed
  36. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  37. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 - PubMed
  38. Chem Pharm Bull (Tokyo). 2005 Jan;53(1):32-6 - PubMed

Publication Types

Grant support